9-(1,3-dihydroxy-2-propoxymethyl)guanine for Cytomegalovirus Infections in Patients with the Acquired Immunodeficiency Syndrome
- MICHAEL C. BACH, M.D.;
- SANDRA P. BAGWELL, M.D.;
- NANCY P. KNAPP, M.D.;
- KENT M. DAVIS, M.D.; and
- PETER S. HEDSTROM, M.D.
Excerpt
Disseminated cytomegalovirus infection is a major cause of mortality in patients with the acquired immuno-deficiency syndrome (1) as well as in other immunosuppressed patients including bone marrow transplant recipients (2). We have had recent positive results with the use of 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG), a new nucleoside antiviral agent, in halting progressive hemorrhagic retinitis and symptomatic pneumonitis due to cytomegalovirus. We report our experience with DHPG in three patients with the acquired immunodeficiency syndrome.
Patient 1: A 31-year-old man was diagnosed as having the acquired immunodeficiency syndrome in November 1983 when he developed Pneumocystis carinii pneumonia. In June 1984 he developed a
This 100-word excerpt has been provided in the absence of an abstract.
Acknowledgments
ACKNOWLEDGMENTS: The authors thank the virology laboratory at Maine Medical Center for their careful techniques; Drs. R. Luke and J. Fanning for their help in histologic diagnoses; the Audio-Visual Department of the Maine Medical Center for photographs; Burroughs-Wellcome Co. and L. E. Kirk, M.S., for supplying the DHPG used in therapy; the nursing staff on P3CD, Maine Medical Center, for their care of patients with the acquired immunodeficiency syndrome; and Joanne Burton for secretarial assistance.
Article and Author Information
-
▸Requests for reprints should be addressed to Michael C. Bach, M.D.; 15 Lowell Street; Portland, ME 04102.
Most Read
